Company intelligence / Profile preview

Apex Labs

Vancouver*, British Columbia*, Canadaapexlabs.com ↗

Ownership: Private
Development stage: Other

Overview

Apex Labs has developed a low-dose synthetic psilocin product targeting PTSD, especially in Veterans and First Nations. The company has received Health Canada approval for North America's first take-home clinical trial with this therapy. Clinical development focuses on patient-driven outcomes and includes partnerships to ensure secure supply chains. No published Phase 2 results yet.

Therapeutic areas: Psychiatry
Modalities: Small molecules (synthetic psilocin/psilocybin)Botanically-sourced APIs (psilocybin derivatives)
Industry: Biotech

Drug pipeline

2 assets

APEX-002

1 more asset in the full pipeline.

Partnerships

Joint Venture Agreement with Innovate for cultivation, extraction, formulation, import/export of controlled substances supporting clinical trials.Collaboration with leading patient advisory groups and teams experienced in MDMA/PTSD trials.

Beyond the preview

Go deeper on Apex Labs.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Apex Labs.